Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Treated as a loss-making company. None of the usual models had enough data, so this uses Net asset value and Discounted cash flow instead.
ACCE opinionBeyond Air Inc. Common Stock (XAIR)
Fair value
Not available
ACCE price target
$1.46
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $2.09 at the close on 23 Oct 2026, 22:00 CEST.
Models: Net asset value and Discounted cash flow.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
19
out of 100
Analysts
100% buy
2 covering
P/E
0.0x
forward 0.0x
1-year return
-95.0%
Dividend yield
0.00%
Beyond Air Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Beyond Air makes nitric oxide delivery systems, including the LungFit platform for treating patients on mechanical ventilation and a device line for hospital use, with its gas generation and delivery hardware sold alongside disposable consumables. The bull case rests on a regulated medical gas product that could be hard to replicate, but the financials leave little room for error: revenue growth of 0.5%, a 4.2% gross margin, and an operating margin of -374.0% show a company spending far more than it earns on a market cap of about $2M. The return on equity of -519.5% means the balance sheet is already stretched, so any path to value depends on a near-term regulatory or commercial catalyst converting into durable revenue and funding. The score of 19/100 and absence from any index reflect this profile. On the data available, this reads as a distressed micro-cap rather than a compounding medical device business, and it warrants a deeper look only if the dilution and cash runway questions can be answered satisfactorily.
⚠ Investor warnings · 5 flagsAI-assisted·How I use AI
severe
Cash burn exceeds market value
Free cash flow is $-19,169,000 against a $2M market cap, and operating margin is -374.0%. The company cannot fund that burn from its equity value, so it depends on outside capital.
high
Heavy leverage on negative equity
Debt/Equity of 3.82 with ROE at -519.5% means losses are eroding a thin equity base while debt stays large.
high
Score collapse over 90 days
The ACCE score fell from 50 to 19 in 90 days, with the quality sub-score at 13 and momentum at 17.
moderate
Revenue growth has stalled
Revenue grew only +0.5% YoY despite a 5-year CAGR of +54.5%, so recent growth has decelerated sharply.
moderate
Price well above ACCE target
The stock trades 43.2% above the ACCE price target of $1.46 against a price of $2.09.
AI research notes
AI-assisted·How I use AIWritten Oct 24, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Analysts are close to unanimous, with every rating on file at Buy or Strong Buy, though only two analysts cover the stock.
Earnings per share beat expectations, coming in at 11.00 against a forecast of -8.60 in the latest quarter.
Revenue grew an average of 54.5% per year over five years, showing the business has expanded quickly in the past.
Why it could disappoint
Revenue grew only 0.5% over the last year, a sharp slowdown from its longer-term pace.
Free cash flow over the last twelve months was negative at -$19M, so the business is burning cash.
Return on equity of -519.5% and debt to equity of 3.82 show shareholders' capital is eroding under heavy borrowing.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 9, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where XAIR's valuation models land
Price
$2.09
Model fair valueConfidence: low
about $4.88
Model
Fair value
Upside
Net asset value
Discounted cash flow
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores